Inclusion Criteria:

- Squamous cell carcinoma of the head and neck in patients with unresectable recurrent
disease or distant metastasis or patients who fail conventional radiation therapy
and/or chemotherapy and refuse surgical salvage.

- Presence of cervical metastasis that is able to be accessed for injection

- Biopsy accessible tumor (metastatic or primary)

- >18 years of age.

- The following laboratory values obtained ≤14 days prior to registration:

- ANC ≥1500

- PLT ≥100,000

- Hgb ≥ 9.0 g/dL

- Alkaline phosphatase ≤3 x UNL

- AST ≤3 x UNL

- Creatinine ≤1.5 x UNL

- Life expectancy ≥6 months.

- ECOG performance status 0, 1, or 2.

- No chemotherapy for prior 4 weeks.

Exclusion Criteria:

- Pregnant women.

- Nursing women.

- Men or women of childbearing potential who are unwilling to employ adequate
contraception (condoms, diaphragm, birth control pills, injections, intrauterine
device {IUD}, abstinence.)

- Known HIV infection.

- Concurrent use of systemic immunosuppressants.

- Other immunocompromising condition that in the opinion of the physician renders the
patient a poor candidate for this trial.

- Other active cancer requiring therapy to control the disease.

- Unwillingness to return for follow-up evaluations over a period of up to 2 years
following completion of protocol therapy.

- Other intercurrent medical problems that, in the opinion of the investigator, would
make participation in the study hazardous for the patient

- Patients in whom the otolaryngologist, radiation oncologist, and medical oncologist
can not agree on a consensus node to treat.

- Patients with CNS metastasis or involvement of sites where an inflammatory response
would constitute an immediately life threatening situation.